Patent: 10,119,976

Summary for Patent: 10,119,976

Title:	Method of assessing risk of PML
Abstract:	The invention relates to methods of assessing a patient\'s risk of developing Progressive multifocal leukoencephalopathy (PML).
Inventor(s):	Bloomgren; Gary Lewis (Concord, MA), Bozic; Carmen (Newton, MA), Lee; Sophia (Waltham, MA), Pace; Amy (Brookline, MA), Plavina; Tatiana (North Reading, MA), Subramanyam; Meena (Stoneham, MA)
Assignee:	Biogen MA Inc. (Cambridge, MA)
Application Number:	14/893,989
Patent Claims:	see list of patent claims

US Patent 10,119,976: JCV Antibody-Titer Risk Stratification for PML and Anti-VLA-4 Treatment Selection

United States Patent 10,119,976 claims methods that use JC virus (JCV) antibody titer to stratify Progressive Multifocal Leukoencephalopathy (PML) risk in multiple sclerosis (MS) patients who meet a negative prior immunosuppressant exposure classification, then use that stratification to guide anti-VLA-4 therapy selection, including natalizumab. The patent’s core novelty is not the existence of JCV antibody risk stratification, but the specific claim logic tying (i) a prior-exposure-limited patient group to (ii) fixed titer thresholds (0.9, plus higher alternatives) and (iii) an explicit decision framework for anti-VLA-4 suitability and treatment initiation/continuation.

The commercial landscape around natalizumab PML risk is mature, with multiple patent families and regulatory guidance already covering JCV antibody testing and risk models. As a result, validity and enforceability in the US likely hinge on whether this patent’s specific combination of conditions, threshold indexing, and timing/multi-sample logic is sufficiently distinct over the known art, and whether those limitations are consistently supported in the specification.

---

What does the patent actually claim (claim-by-claim structure)?

The asserted claim set (as provided) is dominated by three method clusters:
1) Single-sample JCV antibody titer evaluation tied to negative prior immunosuppressant exposure status and a threshold at 0.9 (with dependent claims expanding threshold options).
2) Multi-sample / longitudinal JCV antibody titer evaluation using multiple measurements and a two-threshold decision scheme.
3) Treatment selection (anti-VLA-4, specifically natalizumab) based on being classified “lower risk,” and an MS treatment method.

Cluster A: Single-sample risk evaluation with explicit 0.9 logic

• Claim 1: Method of evaluating a patient’s PML risk by determining JCV antibody titer in a biological sample, limited to a patient with negative prior immunosuppressant exposure classification.
  • If titer > pre-determined level, patient is “higher risk.”
  • If titer ≤ 0.9 index level, patient is “lower risk.”
• Claim 2: pre-determined level is 0.9.
• Claims 3-4: pre-determined level is 1.2 or 1.5.
• Claims 5-6: the “negative prior immunosuppressant exposure classification” is defined as being free of a non-anti-VLA-4 immunosuppressant therapy for a period of 1, 3, or 5 years (Claim 5) or for the patient’s lifetime (Claim 6).
• Claims 7-9: if lower risk, patient is “suitable for treatment with an anti-VLA-4 therapy,” then administering anti-VLA-4; anti-VLA-4 is natalizumab.

Cluster B: Prior natalizumab exposure is permissible

• Claim 10: patient has previously received an anti-VLA-4 therapy.

Cluster C: Longitudinal / second-and-further titer logic

• Claim 11: determine a second or further JCV antibody titer after a later time period.
  • Decision logic is asymmetric across timepoints:
  • If titer in multiple samples is >0 but ≤ pre-determined level, patient is lower risk.
  • If titer is > pre-determined level in the two or more samples, patient is higher risk.
• Claims 12-14: thresholds for longitudinal version are 0.9, 1.2, 1.5.
• Claims 15-17: time period between samples is 6 months, 12 months, or 18 months.
• Claims 18-19: two or more samples can be consecutive; and if titer in every sample is ≤ pre-determined level, classify lower risk.
• Claims 20-21: if titer in every sample is > pre-determined level, classify higher risk; during the period patient may have received anti-VLA-4 therapy.

Cluster D: Additional independent method claim variants

• Claim 22: a second independent method for evaluating risk using only the single threshold logic at ≤0.9 plus negative prior immunosuppressant exposure classification.
• Claims 23-24: administer anti-VLA-4 antibody (natalizumab) if lower risk.
• Claims 25-26: MS treatment method: administer anti-VLA4 antibody responsive to JCV antibody titer ≤0.9 in a patient with negative prior immunosuppressant exposure classification.

---

What is the patent’s practical decision rule for clinicians?

At the claim level, the decision rule is explicit:

1) Confirm the patient is in a “negative prior immunosuppressant exposure classification.” This is not “JCV-seronegative,” but immunotherapy exposure history limited to non-anti-VLA-4 immunosuppressants being absent for a defined period (1/3/5 years) or lifetime.

2) Measure JCV antibody titer (with index cutoffs).

• Lower risk if titer ≤ 0.9 (or if using dependent longitudinal claims: consistently ≤ threshold, or >0 but ≤ threshold, depending on the timepoint logic).
• Higher risk if titer > threshold (threshold adjustable via dependent claims at 0.9/1.2/1.5).

3) If lower risk, classify the patient as suitable for anti-VLA-4, then treat with natalizumab.

In effect, the patent claims a constrained MS population: it does not define a full-spectrum JCV risk model for all MS patients, but a slice based on prior immunosuppressant exposure status and specific titer thresholds.

---

How does this sit within the existing US PML risk model for natalizumab?

The patent operates in the regulatory and commercial orbit created by natalizumab’s PML risk management using JCV serostatus and JCV antibody index. The “0.9” index cutoff aligns with widely used clinical cutoffs that appear in natalizumab risk stratification frameworks (commonly separating lower vs higher risk JCV index categories around 0.9). The inclusion of index levels 0.9, 1.2, 1.5 suggests the patent’s claim language is built to cover multiple thresholding conventions used across internal risk models and clinical practice.

Separately, natalizumab labeling and associated risk stratification frameworks explicitly incorporate:

• prior immunosuppressant use, and
• duration of treatment (natalizumab exposure time), and
• JCV antibody status/index.

The patent claims a subset where “prior immunosuppressant exposure classification” is “negative,” then uses JCV antibody index thresholds to make a treatment suitability decision.

Sources reflect that the clinical field uses JCV antibody index testing to estimate PML risk and that treatment choices depend on these metrics. Janssen’s professional materials and the FDA label are central references for the general model; they do not necessarily contain the exact longitudinal decision tree and threshold parameterization claimed here, but they establish the baseline that JCV antibody testing is a standard risk management approach. [1-3]

---

Where the patent’s claims likely concentrate novelty (and litigation friction)

1) Combining “negative prior immunosuppressant exposure” with fixed JCV index cutoffs

Many earlier disclosures teach PML risk stratification using JCV antibody testing and incorporate prior immunosuppressant exposure. This patent’s key claim-level move is that the patient inclusion criterion (negative non-anti-VLA-4 immunosuppressant exposure for a defined period) is tightly coupled to the decision thresholds. That linkage can be a novelty lever if earlier art either:

• uses different time windows,
• uses different exposure definitions,
• applies the JCV threshold without the same prior exposure restriction, or
• does not explicitly use this restricted subgroup to determine “suitability for anti-VLA-4.”

2) Multiple threshold options in dependent claims

Claims explicitly recite 0.9, 1.2, 1.5 as “pre-determined level” values. This expands coverage to different thresholding methods. From an infringement standpoint, it also makes the claim set more robust: if an accused method uses 0.9, 1.2, or 1.5, it potentially lands within claim scope. From a validity standpoint, however, broad threshold enumeration can create prior-art alignment risk if the same threshold values are already used in published frameworks.

3) Longitudinal logic (Claim 11)

Claim 11 introduces a multi-sample scheme with:

• second/further sampling after specified periods (6/12/18 months),
• decision logic tied to whether titers remain below or above threshold across samples,
• an explicit caveat that anti-VLA-4 can be administered during the period.

Prior disclosure may cover retesting JCV indices longitudinally, but the exact claim logic (including the handling of “above zero but at or below” and the two-sample comparison rule) can be a focal point for both validity and infringement.

4) Anti-VLA-4 treatment selection language

Claims 7-9 and 23-26 convert risk classification into a treatment-selection/administration decision, anchored to natalizumab. The enforceability of method-to-use claims depends on whether prior art discloses not only risk assessment but also treatment decision steps with equivalent thresholds.

Given natalizumab’s regulatory materials, it is plausible that earlier art already describes the treatment selection concept broadly. The patent’s enforceability likely depends on whether those materials disclose:

• the same threshold cutoffs,
• the same negative prior immunosuppressant definition, and
• the same decision step language tied to “suitable for treatment” and “administer anti-VLA-4 antibody” based on the classification.

---

Patent landscape: what matters for freedom-to-operate (FTO) and invalidity

Because the claims are tightly aligned to the established natalizumab PML management framework, the US landscape for this topic is dense. The most important landscape questions for business decision-makers are these:

1) Do earlier patents or published applications disclose the same constrained combination of:

• JCV antibody index testing,
• defined “negative prior immunosuppressant exposure,” and
• fixed index cutoffs at 0.9 (and/or 1.2/1.5),
• followed by natalizumab treatment selection?

2) Is the longitudinal retesting logic already claimed elsewhere with the same sampling windows (6/12/18 months) and similar decision rules?

3) Do other families claim “administration” methods tied to the same thresholds, turning risk models into actionable treatment decisions?

4) Do later continuation applications or related families broaden or narrow these limitations?

What is the landscape anchor point?

The public record for natalizumab PML risk management includes the FDA labeling and manufacturer risk tools reflecting clinical thresholds and risk logic. Those documents are not necessarily patent documents, but they signal what was known and clinically implemented. Patentability of incremental method logic often fails if the same logic is already described as standard of care.

For example:

• FDA label includes JCV antibody testing and PML risk management approaches. [1]
• Manufacturer risk and clinical guidance for JCV index-based risk stratification exists in professional materials. [2-3]

The patent landscape for JCV index-based PML risk prediction has been active for years. This particular patent, with its index cutoffs and prior immunosuppressant constraints, sits inside that mature space.

---

Claim-by-claim enforceability risk map (US litigation lens)

Highest enforceability friction

• Claims 1, 7, 8, 9, 22, 23, 25, 26 (single-sample decision tied to ≤0.9 and natalizumab administration)
  • Reason: JCV index testing and treatment selection are heavily established in regulatory and clinical materials; prior art often teaches risk stratification plus treatment decisions.

Moderate enforceability friction

• Claims 3-4, 12-14 (thresholds at 1.2 and 1.5)
  • Reason: adds specificity but may still match earlier models. The more threshold values used, the more likely at least one is known.

Potentially strongest novelty angle

• Claim 11 (longitudinal multi-sample logic with defined retesting intervals and decision tree)
  • Reason: the patent’s unique contribution may lie in the precise multi-sample decision logic and sampling period constraints.

Potential “overbreadth” / clarity friction

• “negative prior immunosuppressant exposure classification” defined by being free of non-anti-VLA-4 immunosuppressant for 1, 3, or 5 years or lifetime.
  • This may create interpretive boundaries. If prior art defines prior immunosuppressant exposure differently (e.g., “at any time” or different duration cutoffs), infringement and validity can turn on claim construction.

---

Commercial implications: what would an accused method have to do to avoid this patent?

To step outside literal scope, an accused method would typically need one of the following:

• Use a patient group not matching the “negative prior immunosuppressant exposure classification” as claimed (e.g., include patients with prior non-anti-VLA-4 immunosuppressant exposure within the forbidden windows).
• Use a different treatment decision trigger than the “≤0.9 index level” (or the enumerated threshold values when selecting dependent claims).
• Avoid the longitudinal decision logic if relying on Claim 11.
• Use anti-VLA-4 therapies that are not natalizumab if the relevant claim requires natalizumab specifically (claims 9, 24, 26).

In practice, most clinical implementations of natalizumab risk management use JCV index testing and prior immunosuppressant history. That means avoidance would require non-standard workflow design or materially different decision thresholds.

---

Key Takeaways

• US Patent 10,119,976 claims a JCV antibody index threshold-based PML risk stratification method restricted to MS patients with negative prior non-anti-VLA-4 immunosuppressant exposure, with treatment suitability leading to anti-VLA-4 therapy (explicitly natalizumab in multiple claims).
• The patent’s claim set is anchored on index cutoffs at 0.9, with dependent thresholds at 1.2 and 1.5, and it adds a longitudinal retesting decision tree using sampling intervals of 6, 12, or 18 months.
• Enforceability risk is highest for the single-sample “≤0.9 then treat with natalizumab” logic because JCV index-based risk management for natalizumab is already reflected in regulatory and clinical guidance.
• The multi-sample logic in Claim 11 is the most likely area where the patent can defend against prior art based on the specific claim logic and timing structure, assuming the specification supports those elements.
• For FTO, the most meaningful risk driver is whether competitors replicate the same combination of (i) negative prior immunosuppressant exposure definition, (ii) the same index thresholds, and (iii) the same treatment decision steps tied to natalizumab.

---

FAQs

1) What threshold is the patent’s main lower-risk cutoff?
The principal lower-risk cutoff is JCV antibody index ≤ 0.9 in the independently stated method claims.

2) Does the patent cover longitudinal retesting?
Yes. Claim 11 requires determining a second or further JCV antibody titer and classifies risk based on how titers compare to a pre-determined index level across samples, with retesting periods of 6, 12, or 18 months in dependent claims.

3) Is natalizumab required in all claims?
No. Natalizumab is explicitly required in multiple dependent claims (e.g., Claims 9, 24, 26). The independent method claims can be broader regarding anti-VLA-4 unless constrained by those dependents.

4) What makes the “negative prior immunosuppressant exposure classification” important legally?
It narrows the eligible patient population to those free from non-anti-VLA-4 immunosuppressants for defined periods (1/3/5 years) or lifetime, which can distinguish the claimed methods from broader “all-comers” JCV risk stratification models.

5) Where is the likely strongest differentiation from prior art?
The likely strongest differentiation is the specific longitudinal retesting and decision logic in Claim 11, including the multi-sample threshold rule and the defined sampling intervals.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Tysabri (natalizumab) prescribing information (PML risk management and JCV testing guidance). FDA.
[2] Janssen Biotech, Inc. (n.d.). TYSABRI JCV risk stratification resources / clinical guidance (JCV antibody index and PML risk categories).
[3] European Medicines Agency. (n.d.). Tysabri assessment materials and risk management information for PML (JCV antibody index risk framework). EMA.

Details for Patent 10,119,976

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	November 23, 2004	10,119,976	2034-05-27